Trial Profile
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed or Refactory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; AT 101
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 11 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 17 Dec 2018 Status changed from suspended to active, no longer recruiting.